RxDoctor Payments Data

Jagdish Sachdeva, MD

Internal Medicine · Southgate, MINPI 1295891067

Payments from drug & device makers

$1,982in general payments, 2019–2025

Across 75 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$633
  • GSK$486
  • Pfizer$187
  • Novo Nordisk$141
  • Esperion Therapeutics, Inc.$125
  • Amgen$98
  • plus $312 from 9 others

What the payments were for

  • Food & beverage$1,95298%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,982 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$76,169
Medicare patients
117
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$78,260
MounjaroTirzepatide57$73,183
JardianceEmpagliflozin45$57,482
OzempicSemaglutide41$46,501
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$40,379
JanumetSitagliptin Phos/Metformin Hcl34$39,332
FarxigaDapagliflozin Propanediol31$30,742
JanuviaSitagliptin Phosphate20$18,972
EntrestoSacubitril/Valsartan21$18,535
RybelsusSemaglutide13$12,022
LinzessLinaclotide12$6,105
Atorvastatin Calcium300$3,963
Humalog Kwikpen U-100Insulin Lispro11$3,907
Levothyroxine Sodium289$3,572
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$3,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$187$78,26078 claims
Lilly USA, LLCMounjaro$47$73,18357 claims
Novo NordiskOzempic, Rybelsus$141$58,52354 claims
MerckJanumet, Januvia$24$58,30454 claims
GSKTrelegy Ellipta$486$40,37949 claims
AstraZenecaFarxiga$633$30,74231 claims
NovartisEntresto$30$18,53521 claims
AbbVieLinzess, Synthroid$44$7,60533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southgate

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →